Pharmicell (005690.KS) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · South Korea · ISIN KR7005690003
Pharmicell financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 64.85 bn KRW | 114.06 bn KRW |
| Gross profit | 21.33 bn KRW | 50.68 bn KRW |
| Operating income | 4.66 bn KRW | 34.30 bn KRW |
| EBIT | 6.37 bn KRW | 34.91 bn KRW |
| Net income | 6.33 bn KRW | 40.29 bn KRW |
| Diluted EPS – continuing operations | 105.51 KRW | 671.44 KRW |
Full history since 2010, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Pharmicell
Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells autologous drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to improve the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty. The company's products under development include Cellgram_LC to treat hepatic insufficiency; Cellgram_ED for treating impotence; and Hearticellgram_AMI, a cardiac disease drug. It develops and produces intermediates of raw material medicines, such as nucleosides and mPEGs; and low dielectric constant material, eco-friendly flame retardant, polyol synthesis catalyst, PET catalyst, etc. In addition, the company provides Half-Serum DMEM, a cell culture medium; and PharmiSTEM culture medium for mesenchymal stem cells, as well as clinical development and commercialization services for new drugs. Further, it operates stem cell bank under Twelve brand name; and develops and sells stem cell culture media cosmetics. The company was formerly known as FcB2welve Co., Ltd and changed its name to Pharmicell Co., Ltd. in September 2011. Pharmicell Co., Ltd. was founded in 1968 and is headquartered in Seoul, South Korea.
More stocks
- Revenio Group Corporation (REG1V.HE)
- MCLON JEWELLERY Co.Ltd. (300945.SZ)
- Xinjiang Torch Gas Co Ltd (603080.SS)
- Taiwan Mask Corp (2338.TW)
- Byggmax Group AB (BMAX.ST)
- Angel Oak Financial Strategies Income Term Trust (FINS)
- Sportsoul Co. Ltd. A (001300.SZ)
- Guangzhou Jinzhong Auto Parts Manufacturing Co. Ltd. (301133.SZ)
- Cuckoo Homesys Co Ltd (284740.KS)
- Lungteh Shipbldg Co Ltd (6753.TW)
- Jinsanjiang (Zhaoqing) Silicon Material Company Limited (301059.SZ)
- Shenzhen Neoway Technology Co Ltd (688159.SS)
Not investment advice. All data without warranty, price as of 11.11.2026. Details in the risk notice.